Clinical Trial Update: Human Papilloma Virus Vaccine Safety and Immunogenicity Trial in Young Adolescent Women With GSK Bio HPV-16/18. [Phase 3]

View source ↗

Summary

A Phase 3 trial by GlaxoSmithKline evaluating the safety and immunogenicity of the HPV-16/18 vaccine in young adolescent women has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Human Papillomavirus Infection

Drugs mentioned

• Cervarix (human papillomavirus vaccine, bivalent)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Infections, Papillomavirus | Phase 3 | Status: COMPLETED